Semin Thromb Hemost
DOI: 10.1055/a-2619-2485
Review Article

Coagulation abnormalities associated with COVID-19: a narrative review.

Massimo Franchini
1   Hematology and Transfusion Medicine, Azienda Ospedaliera Carlo Poma, Mantua, Italy (Ringgold ID: RIN9253)
,
Daniele Focosi
2   North-Western Tuscany Blood Bank, Pisa University Hospital, Pisa, Italy (Ringgold ID: RIN9257)
,
Pier Mannuccio Mannucci
3   Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico and University of Milan, Milan, Italy
› Author Affiliations

Coronavirus disease 2019 (COVID-19), a viral respiratory illness caused by severe acute respiratory disease coronavirus 2 (SARS-COV-2), has caused in the last five years a global pandemic of unprecedented scale in the modern era. Other than the typical respiratory symptoms, patients suffering from moderate to severe COVID-19 are at risk of developing a peculiar systemic coagulopathy, known as COVID-19-associated coagulopathy. In addition to a predominantly hypercoagulable state, COVID-19 patients may experience hemorrhagic complications triggered by the viral infection. The current knowledge on the underlying molecular mechanisms, the laboratory and clinical characteristics of coagulation abnormalities associated with COVID-19, along with their management, will be summarized in this narrative review.



Publication History

Received: 12 March 2025

Accepted after revision: 19 May 2025

Accepted Manuscript online:
23 May 2025

© . Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor , NY 10001 New York, USA